Browsing by Author Michael, Michael

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2006Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul L.; Thomson, Jacquelyn A.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAddition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity., Clinical Colorectal Cancer, vol.6,(2),2006,pp 146-151
2005Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, P.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAustralian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients., British Journal of Cancer, vol.92,(5),2005,pp 832-837
2012Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance testClarke, Stephen; Booth, R; Cullinane, Carleen; Francis, P A; Hatzimihalis, A; Michael, Michael; Milner, Alvin D.; O'Kane, C; Schlicht, S; Northern Clinical School: Kolling InstituteDocetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test, Cancer Chemotherapy and Pharmacology, vol.69, 1, 2012,pp 125-135
2007Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising EfficacyBeale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteModification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy, Clinical Colorectal Cancer, vol.6,(8),2007,pp 578-582
2009Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerChua, Wei; Dhillon, Haryana; Clark, SJ.; Goldstein, D; Iacopetta, Barry J.; Lee, CK.; Michael, Michael; Mitchell, Paul L.; Concord Clinical School: Medicine; Central Clinical School: MedicineMolecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer, British Journal of Cancer, vol.101, 6,pp 998-1004
2012A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancerClarke, Stephen; Pavlakis, Nick; Clingan, Philip R.; de Boer, Richard; Johnston, Michael; Michael, Michael; Concord Clinical School: Medicine; Northern Clinical School: MedicineA multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer, Oncology reports, vol.28, 3, 2012,pp 763-767
2015Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCClarke, Stephen; Abdi, E; Button, Peter; Clingan, Philip R.; Do, Hongdo; Dobrovic, Alexander N; Gregory, Daniel; Michael, Michael; Nott, Louise M; Solomon, Benjamin; White, Shane C; Zimet, A; Northern Clinical School: Kolling InstituteMulticenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC, Asia-Pacific Journal of Clinical Oncology, vol.11, 1, 2015,pp 4-14
2016Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapyKhasraw, Mustafa; Ananda, S; Michael, Michael; NH&MRC Clinical Trials CentreNeuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy, Expert Review of Anticancer Therapy, vol.16, 4, 2016,pp 391-401
2013Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factorsClarke, Stephen; Pavlakis, Nick; Desai, Jayesh; Gibbs, Peter; Karapetis, Christos; Michael, Michael; Pricek, T.J.; Tabernero, Josep; Tebbutt, Niall C; Concord Clinical School: Medicine; Northern Clinical School: MedicineOverview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors, Critical Reviews in Oncology / Hematology (online), vol.85, 2, 2013,pp 121-135
2006Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination.Clarke, Stephen; Zalcberg, John; Di Iulio, Juliana; Ellis, Andrew; et, al; Gurtler, Volker; Hicks, Rod J.; Michael, Michael; Milner, Alvin D.; Mitchell, Paul L.; Scott, Andrew; Thompson, Mick; Concord Clinical School: ANZAC Research Institute; School of Public Health: NH&MRC Clinical Trials CentreRelationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(26),2006,pp 4228-4235
2017TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTGGebski, Val; Miller, Danielle; O'Connell, Rachel; Simes, Robert John; Verghis, Jaclyn; Boussioutas, A; et al, Various; Findlay, M; Haustermans, Karin; Kron, Thomas; Leong, T; Michael, Michael; Smithers, B. Mark; Willis, David; Zalcberg, John; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreTOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG, Annals of Surgical Oncology, vol.24, 8, 2017,pp 2252-2258